Position in BHVN
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$342,567
+$139,341 QoQ
Shares Held
23,022
-4.2% QoQ
Ownership
0.015%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#163
of 294 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in BHVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Coastal Bridge Advisors, LLC holds $11,640,553 across 14 Biotechnology names. BHVN ranks #8 (2.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DNA |
Ginkgo Bioworks Holdings, Inc.
|
276,817 | $2,743,256 | |
| 2 | INCY |
Incyte Corp
|
21,815 | $2,472,948 | |
| 3 | URGN |
UroGen Pharma Ltd.
|
37,000 | $1,361,600 | |
| 4 | PRAX |
Praxis Precision Medicines, Inc.
|
3,846 | $1,287,602 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
14,500 | $1,134,915 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,614 | $1,006,393 | |
| 7 | SPRY |
ARS Pharmaceuticals, Inc.
|
55,838 | $447,262 | |
| 8 | BHVN |
Biohaven Ltd.
This page
|
23,022 | $342,567 |
All Filings in BHVN
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $342,567 | 23,022 | Shares | Sole | 2026-08-17 | |
| 2026-03-31 | $203,226 | 24,022 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $279,958 | 24,797 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $506,917 | 33,772 | Shares | Sole | 2025-11-03 | |
| 2025-06-30 | $520,616 | 36,897 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||